Premium
Individual Difference in the Pharmacokinetics of a Drug, Pravastatin, in Healthy Subjects
Author(s) -
Ogawa Katsutoshi,
Hasegawa Setsuo,
Udaka Yuko,
Nara Keinosuke,
Iwai Shinichi,
Oguchi Katsuji
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270003257232
Subject(s) - pravastatin , cmax , pharmacokinetics , outlier , medicine , pharmacology , mathematics , statistics , cholesterol
The purpose of this investigation was to determine whether there were individual pharmacokinetic differences of a drug, pravastatin. Furthermore, the percentage of subjects who showed pharmacokinetic differences was determined. A single oral dose of pravastatin 10 mg was administered to 84 Japanese healthy male subjects. Serum concentrations of pravastatin were measured for 8 hours postdose. Area under the concentration‐time curve (AUC) and peak concentration (C max ) were determined as primary evaluation parameters. An outlier was defined as follows: Outlier 1 < Q1 ‐ (Q3 ‐ Q1) × 1.5 or Q3 + (Q3 ‐ Q1) × 1.5 < Outlier 1, Outlier 2 < Q1 ‐ (Q3 ‐ Q1) × 3 or Q3 + (Q3 ‐ Q1) × 3 < Outlier 2. Subjects who were outliers were regarded as having an individual difference in pharmacokinetic behavior. In AUC and C max , 4 of 84 subjects (4.8%) were higher outliers. Of these 4 subjects, 2 were high outliers in both AUC and C max . No subjects were low outliers. It was concluded that a significant individual difference in the pharmacokinetics of pravastatin was observed in 4.8% of the subjects (4/84) .